{"id":"ticagrelor-followed-with-methoxyflurane","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Ventricular pauses"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Dizziness or sedation"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ticagrelor is a direct P2Y12 adenosine diphosphate receptor antagonist that prevents platelet activation and aggregation, reducing thrombotic events. Methoxyflurane is a volatile anesthetic and analgesic agent that acts through multiple mechanisms including NMDA receptor antagonism, providing rapid pain relief. The combination leverages ticagrelor's antiplatelet effects with methoxyflurane's analgesic properties for acute pain management in cardiovascular settings.","oneSentence":"Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while methoxyflurane provides rapid analgesia through NMDA receptor modulation and other mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:12:35.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain relief in patients receiving ticagrelor for cardiovascular indications"},{"name":"Breakthrough pain management in acute coronary syndrome or other thrombotic conditions"}]},"trialDetails":[{"nctId":"NCT04442919","phase":"PHASE4","title":"Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2020-06-01","conditions":"Unstable Angina","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brilique + Penthrox"],"phase":"marketed","status":"active","brandName":"Ticagrelor followed with Methoxyflurane","genericName":"Ticagrelor followed with Methoxyflurane","companyName":"Collegium Medicum w Bydgoszczy","companyId":"collegium-medicum-w-bydgoszczy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while methoxyflurane provides rapid analgesia through NMDA receptor modulation and other mechanisms. Used for Acute pain relief in patients receiving ticagrelor for cardiovascular indications, Breakthrough pain management in acute coronary syndrome or other thrombotic conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}